Li Chen
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
CHST1 Drives Immunotherapy Resistance in Triple-Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF-CCL20-Macrophage Axis.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 29, 2026
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: December 23, 2025
Interferon-induced senescent CD8+ T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer.
Journal: Science translational medicine
Published: September 10, 2025
CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 14, 2025
Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
Journal: Molecular cancer
Published: April 28, 2025
Intramammary benign vascular proliferative lesions on MRI during neoadjuvant chemoimmunotherapy with camrelizumab in TNBC patients.
Journal: European journal of radiology
Published: April 11, 2025
HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer.
Journal: Cell metabolism
Published: February 28, 2025
Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy.
Journal: Cell reports. Medicine
Published: February 07, 2025
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: September 13, 2023
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
Journal: Molecular cancer
Published: January 13, 2022
Last Updated: 09/26/2026